LBLara Berklite

Lara Berklite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lara Berklite has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

    by Esraa Eloseily, Ivanna Romankevych, Taskin Sabit, Lara Berklite, Sarangarajan Ranganathan, Paul Rosen, Michael Henrickson, Jennifer Huggins, Grant Schulert, Alexei Grom

    Objective: Systemic juvenile idiopathic arthritis (sJIA) is a chronic inflammatory disease characterized by systemic features and arthritis. Macrophage activation syndrome (MAS) is a severe complication of sJIA often involving the liver. MAS confined predominantly to the liver, causing severe hepatitis, has been increasingly recognized. When liver MAS is the primary manifestation, significant hepatic injury can occur; therefore, differentiation from other forms of sJIA-related liver involvement, which may warrant distinct treatment approaches, is required. This study examined liver pathology in patients with sJIA-MAS and explored potential mechanisms. Methods: This retrospective case series analyzed data from 4 patients with sJIA-MAS who presented with liver dysfunction and underwent core liver biopsies at Cincinnati Children’s Hospital Medical Center (2019-2024). Results: Four patients (age range 4-15 years) had elevated transaminases, with 1 meeting MAS criteria and 3 diagnosed with subclinical MAS. Liver biopsies showed portal and sinusoidal inflammatory infiltrates of CD3+ CD8+ T cells and CD163+ macrophages, with extensive hepatocellular damage, including centrilobular parenchymal collapse, multifocal necrosis, and lymphocyte-mediated bile duct injury. One case revealed features of venoocclusive disease, a novel finding. Elevated serum chemokine (C-X-C motif) ligand 9 (CXCL9) and rapid response to emapalumab (anti–interferon γ [anti–IFN-γ]) in all patients suggested IFN-γ–driven liver pathology. Conclusion: This study underscores the critical roles of CD8+ T cells, macrophages, and IFN-γ in sJIA-MAS hepatitis. Future research should explore whether serum biomarkers of IFN-γ activity can differentiate sJIA-MAS from other liver pathologies, such as drug-induced liver injury (methotrexate- or anakinra-induced) and hepatic steatosis, to guide tailored therapies.


  • Benign and Malignant Pediatric Liver Masses: Radiologic-Pathologic Update from the Pediatric LI-RADS Working Group

    by Mitchell A. Rees, Michael R. Acord, Lara E. Berklite, Adina L. Alazraki, Ellen M. Chung, Geetika Khanna, Amy B. Kolbe, Cara E. Morin, Esther Ro, Gary R. Schooler, et al.

    Benign and malignant primary pediatric liver tumors are reviewed, correlating imaging features with the underlying pathology and incorporating updates in imaging technology and tumor classification.


  • Open Access

    Fetal cardiac masses

    by Bhagyashree Rathore, Marissa E. Adamson, Lara E. Berklite, Pradipta Debnath, Beth M. Kline-Fath, Kimberley G. Miles, Cara E. Morin, Kristin A. Schneider

    Although rare in the pediatric population, cardiac tumors represent a significant portion of prenatally detected masses, second only to sacrococcygeal teratomas. Fetal cardiac masses are predominantly benign, with rhabdomyoma being the most common fetal cardiac mass in the setting of tuberous sclerosis. Multiple lesions are pathognomonic for rhabdomyomas and prompt evaluation for tuberous sclerosis. Fibroma, teratoma, and hemangioma are other consistently detected cardiac tumors. In this article, we review the epidemiology, imaging, treatment, and outcomes of these fetal cardiac masses, emphasizing the role of imaging in surveillance, identifying complications, refining the differential diagnosis, and recognizing potential diagnostic pitfalls. Graphical abstract


  • Open Access

    Oncogenic Role of Aberrant EZH2 in Hepatoblastoma

    by Kathryn Glaser, Lara Berklite, Brian T. Hickner, Priyanka Rao, Roma H. Patel, Andrew A. Badachhape, Somak Roy, Emily Schepers, Nikolai A. Timchenko, James I. Geller, et al.

    Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived tumor cell population (cycling Hep T ) enriched for Enhancer of Zeste Homolog 2 ( EZH2) expression, particularly in the aggressive embryonal subtype. Integrative genomic and transcriptomic profiling confirmed EZH2 overexpression. Disruption of the PRC2 complex was evident through mislocalization and reduced expression of SUZ12, a core component. EZH2 overexpression correlated with upregulation of mitotic regulators such as AURKB and Ki67 in human HB gene expression analysis as compared to background liver. Targeted sequencing identified variants of uncertain significance in EZH2 and SUZ12 in 11 of 11 patient tumors. Pharmacologic inhibition of EZH2 with EPZ-6438 reduced proliferation and sensitized HB cells to cisplatin through gene regulation, potentially modulating platinum accumulation both in vitro and in vivo . In summary, EZH2 promotes HB progression through epigenetic silencing and noncanonical signaling pathways. These findings support EZH2’s contribution to HB pathogenesis, therefore identifying it as a novel therapeutic target. STATEMENT OF SIGNIFICANCE: EZH2 is enriched in hepatoblastoma, suggesting its role in early tumorigenesis. Its inhibition, combined with cisplatin, produces synergistic anti-tumor effects, supporting EZH2 as both an oncogenic and therapeutic target.

  • Open Access

    Teratoid Hepatoblastoma—Our Experience

    by Lara Berklite, Sarangarajan Ranganathan

    Hepatoblastomas (HB) are the most common pediatric liver tumor with several subgroups described, of which teratoid HB is the rarest. The aim of this study is to characterize the histologic and phenotypic spectrum of teratoid HB in order to better understand the biology and behavior of these tumors. A retrospective analysis of all teratoid HB diagnosed at a major pediatric hospital as well as the consultation files of one of the authors (SR) was performed with the available clinical data and surgical pathology material reviewed. A detailed immunohistochemical workup was also performed. A total of 28 cases were included from patients ranging from 5 to 84 months of age and a M:F ratio of 1.07:1. Four patients had syndromic associations. In 14/28 cases, the tumors contained primitive glandular elements with histologic and immunophenotypic overlap with the yolk sac tumor which in two cases became predominant in metastatic sites. One case had extensive primitive neural epithelium mimicking a primitive neuroectodermal tumor (PNET). Other unique elements included melanin, mature neuroglial tissue, rhabdomyoblastic differentiation, and neuroendocrine carcinoma-like areas (n = 2). In conclusion, this study provides the largest series of teratoid HB to date with clinical and outcome data, highlights previously undescribed or under-recognized histologic patterns in these tumors, and describes the immunohistochemical profile of these tumors to aid in diagnosis.